At least 350 brand-name medications are expected to cost more in 2026 — including cancer therapies, COVID-19 treatments, vaccines, and drugs for chronic conditions millions of Americans rely on daily. For patients and families already stretched thin by premiums and out-of-pocket costs, these increases make finding prescription help for uninsured and underinsured individuals more urgent than ever.
Why Are So Many Drugs Getting More Expensive in 2026?
Pharmaceutical manufacturers are planning list-price increases on more than 350 branded medications heading into 2026 — a significant jump from the roughly 250 drugs that saw hikes the previous year. The median increase hovers around 4%, which may sound small in isolation, but that math changes quickly when you're talking about specialty drugs that already cost hundreds or thousands of dollars a month.
Several factors are pushing this trend:
- Spreading increases more broadly. Rather than taking steep double-digit hikes on a handful of products, drugmakers are applying modest increases across a larger number of drugs — partly to avoid the political backlash that comes with dramatic single-drug price jumps.
- Getting ahead of Medicare policy changes. New penalties for price hikes that outpace inflation, combined with the rollout of Medicare's drug price negotiation program, are prompting manufacturers to move prices now.
- Rising health costs across the board. Prescription drugs account for nearly a quarter of total U.S. health spending, and that share is expected to grow in 2026, contributing to an overall spike in healthcare costs.
Because list prices are the foundation for how deductibles, coinsurance, and premiums are calculated, these increases affect people across the coverage spectrum — insured, underinsured, and uninsured alike.
Which Types of Medications Are Most Affected?
The 350-drug list spans a wide range of therapeutic categories, but a few areas stand out for their potential impact on patients:
- Cancer treatments: Oncology drugs like Ibrance appear on the list. Even a modest percentage increase can translate to thousands of extra dollars per year for patients in active, long-term treatment.
- COVID-19 vaccines and antivirals: Comirnaty faces a reported 15% price hike, while antivirals like Paxlovid are also included — raising costs for high-risk patients who need early access to reduce hospitalization risk, particularly as public-health coverage programs wind down.
- Chronic disease medications: Drugs for diabetes, heart failure, asthma, and respiratory conditions are seeing adjustments too, hitting patients who are often already managing multiple prescriptions simultaneously.
As costs climb across these categories, more patients are turning to a patient assistance program or medication assistance program to maintain access to therapies they can't afford to go without.
Specific Drugs to Watch in 2026
The table below highlights brand-name drugs either directly cited in 2026 price-hike reporting or representative of the high-cost therapies patients most commonly struggle to afford.
| Drug | Primary Use | Why 2026 Price Changes Matter | | --- | --- | --- | | Ibrance | Breast cancer | Long-term oncology therapy; mid-single-digit increases add up to thousands per year. | | Paxlovid | COVID-19 antiviral | Higher list prices create barriers for high-risk patients as public coverage fades. | | Comirnaty | COVID-19 vaccine | A reported 15% increase raises out-of-pocket costs for boosters. | | Januvia | Type 2 diabetes | Price changes ripple through deductibles and coinsurance for a widely used diabetes drug. | | Entresto | Chronic heart failure | Long-term use makes any price hike especially burdensome for retirees and fixed-income patients. | | Dupixent | Asthma, eczema | As a high-cost biologic, even a small percentage increase means a significant dollar jump. | | Ozempic | Type 2 diabetes | High demand and uneven insurance coverage mean list-price increases hit broadly. |
How Do These Hikes Fit the Bigger Picture?
The 350-drug wave isn't happening in a vacuum. Employers are bracing for healthcare costs to rise by roughly 9% in 2026, with specialty medications and hospital expenses leading the way. Prescription drug spending is a key driver of that growth, and it's why brand name drug financial assistance has become an essential resource — not a last resort — for a growing number of American families.
What Can Patients Do If Their Drug Is on the List?
If you take one of the medications facing a 2026 price increase, here are practical steps to take now:
- Check your plan's 2026 formulary. Find out if your drug has moved to a higher cost-sharing tier, which could mean significantly larger copays or coinsurance.
- Ask your prescriber about alternatives. A generic or biosimilar equivalent may be available and clinically appropriate for your situation.
- Look into a manufacturer assistance program. Many drugmakers offer their own manufacturer assistance programs for patients who qualify based on income or insurance status.
- Enroll in a full-service prescription assistance program. A program like ClariMeds can identify every source of help you're eligible for, handle the paperwork, and manage renewals so your coverage doesn't lapse.
FAQs: 350 Drugs Getting Pricier in 2026
Why are so many manufacturers raising prices at the same time?
Drugmakers are applying modest increases across a broader range of products rather than taking large hikes on a few high-profile drugs. This approach partly reflects pressure from Medicare's new inflation-based penalty structure and the broader political climate around drug pricing.
Will my insurance protect me from these increases?
Insurance helps, but it doesn't insulate you completely. Higher list prices feed directly into how deductibles, coinsurance, and future premiums are calculated — especially for specialty and high-tier drugs. Insured patients can still feel the impact.
Can a prescription assistance program really reduce my costs on expensive brand-name drugs?
Yes. Free brand name medication is genuinely available to eligible patients through manufacturer and nonprofit assistance programs. A full-service prescription assistance program can help you identify which programs you qualify for and manage enrollment on your behalf — covering drugs like Ibrance, Dupixent, Ozempic, and many others on the 2026 price-hike list.
If a drug you depend on is getting more expensive this year, you don't have to absorb that cost alone. ClariMeds is a full-service prescription assistance program that connects uninsured and underinsured patients with free or low-cost brand-name medications through manufacturer and nonprofit assistance programs — and handles the entire process from application to renewal. If you're looking for real help paying for prescriptions in 2026, start your enrollment today and a ClariMeds representative will follow up with you within 24 hours.